Evidence map›Paper›PMID 40322546›Full record

ArticleMolecular and clinical oncology2025

Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer.

Ayako Shiono, Hisao Imai, Satoshi Endo, Shohei Okazaki, Takanori Abe, Atsuto Mouri, Kyoichi Kaira, Ken Masubuchi, Kunihiko Kobayashi, Koichi Minato and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ayako ShionoDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.
Hisao ImaiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.
Satoshi EndoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma 373-8550, Japan.
Shohei OkazakiDivision of Radiation Oncology, Gunma Prefectural Cancer Center, Ota, Gunma 373-8550, Japan.
Takanori AbeDepartment of Radiation Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.
Atsuto MouriDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.
Ken MasubuchiDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma 373-8550, Japan.
Kunihiko KobayashiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.
Koichi MinatoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma 373-8550, Japan.
Shingo KatoDepartment of Radiation Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama 350-1298, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overall survival (OS) among patients with limited-disease small-cell lung cancer (LD-SCLC) receiving chemoradiotherapy can be significantly influenced by subsequent treatments. Thus, the present study aimed to examine the interplay between progression-free survival (PFS), post-progression survival (PPS) and OS in patients with LD-SCLC undergoing chemoradiotherapy. This study retrospectively analyzed 84 patients with relapsed LD-SCLC who received chemoradiotherapy between April 2007 and June 2021. The correlations between PFS and OS as well as PPS and OS post-chemoradiotherapy were analyzed at the individual patient level. Spearman's rank correlation and linear regression analyses revealed a robust correlation between PPS and OS (r=0.76; P<0.05; R

Indexed as

chemoradiotherapylimited-disease small cell lung canceroverall survivalpost-progression survivalprogression-free survival

Identifiers

PMID40322546
PMCPMC12046617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.